The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 This international ...

December 23, 2008 — In the treatment of advanced ovarian cancer, neoadjuvant chemotherapy before surgical debulking may be the new standard of care — especially in countries where the scheduling of a ...

High-volume hospitals with frequent NACT use had the lowest 90-day surgical mortality and longest 60-month survival. NACT reduced perioperative deaths in all hospital types, including those with low ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

How Does Zejula Work in Advanced Ovarian Cancer? In platinum-based chemotherapy, the platinum in the medicine binds to the genetic material (DNA) of cancer cells. This damages the cancer cells and ...

How Does Lynparza Work for Ovarian Cancer? Lynparza is a type of medicine known as poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is a certain protein that helps cancer cells survive and grow. It ...

Women with ovarian cancer have a higher incidence of colorectal cancer, and vice versa, as indicated by standardized incidence ratios. A recent review suggests women with ovarian or colorectal cancer ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

A Strange New World of Cancer Research Has a Cost The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian ...